Despite promising results in preclinical settings, the applicability of RSV to humans has met with only limited success, largely owing to its inefficient systemic delivery and consequently its low bioavailability. To achieve an optimal response of RSV, new strategies are still required to enhance its bioavailability and reduce its perceived toxicity.
No takes yet. Share an insight, caveat, or question.
Paiva‐Santos et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: